Description
Sorafenib
Each film-coated tablet contains Sorafenib tosylate 274 mg equivalent to Sorafenib… … 200mg.
INDICATIONS
LuciSora is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma. • Advanced renal cell carcinoma. • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
DOSAGE AND USE
• 400 mg (2 tablets) orally twice daily without food. • Treatment interruption and/or dose reduction may be needed to manage adverse reactions.
STORAGE
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD. No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNINGS
Keep medicine out of reach of Children. Do not administer LuciSora during Pregnancy and Lactation.
Reviews
There are no reviews yet.